Taking Diabetes to Heart: Using Antihyperglycemic Agents to Reduce Cardiovascular Risk
This activity is supported by a medical education grant from Novo Nordisk, Inc.
Click Here to Manage Email Alerts
Overview
Provider Statement
This activity is provided by Pri-Med Institute.
Support Statement
This activity is supported by a medical education grant from Novo Nordisk, Inc.
Activity Description
In recent years, there has been a paradigm shift in how to individualize the use of antihyperglycemic agents in people with type 2 diabetes mellitus, with cardiac history and risk factors significantly affecting the guidelines’ treatment pathways. In addition, metformin, SGLT2 inhibitors, and GLP-1 receptor agonists have become an integral part of the treatment of patients with diabetes and comorbid cardiac and renal disease. Join expert faculty in this data-driven session as they review the cardiovascular outcomes data on antihyperglycemic agents and discuss strategies to improve the use of these agents in the management of type 2 diabetes mellitus.
Target Audience
The intended audience for this activity is cardiologists and primary care providers focused on managing cardiovascular issues.
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Evaluate outcomes data on antihyperglycemic agents with proven cardiovascular (CV) risk reduction
- Examine current clinical practice guidelines that stress the early use of antihyperglycemic medications to manage CV risk in people with T2DM, regardless of glycemic status Optimize anticoagulant therapy prophylactically and therapeutically across diverse and complex patient populations
Faculty
Christopher Cannon, MD
Cardiovascular Division
Brigham and Women's Hospital
Professor of Medicine
Harvard Medical School
Boston, MA
Tina Kaur Thethi, MD, MPH
Associate Investigator and Endocrinologist
AdventHealth, Translational Research Institute
Orlando, FL
Moderator
Peter Libby, MD
Cardiovascular Specialist
Brigham and Women's Hospital
Mallinckrodt Professor of Medicine
Harvard Medical School
Boston, MA
Reviewers
Meg Oliverio, MD
Gordon Huggins, MD
Accreditation
AMA PRA Category 1 Credits™
Accreditation Statement
Pri-Med Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement
Pri-Med Institute designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AANP
Accreditation Statement
Pri-Med Institute is accredited by the American Association of Nurse Practitioners® as an approved provider of nurse practitioner continuing education. Provider number: 040308.
Designation Statement
This activity is approved for 1.00 contact hour of continuing education, which includes 1.00 hours of pharmacology.
Credit Designation
1.00 AMA PRA Category 1 Credits™ or 1.00 AANP, including 1.00 AANP Pharm
How to Participate in This Activity and Obtain CME Credit
To complete this activity and claim credit, you must answer 2 out of the 3 questions correctly.
Disclosures
The following relevant financial relationships have been disclosed by faculty, and all have been mitigated by Pri-Med Institute.
Tina K. Thethi, MD, MPH: Speaker and Consultant for Novo Nordisk and Bayer. Researcher for AstraZeneca.
Christopher P. Cannon, MD: Researcher for Amgen, Boehringer-Ingelheim, Merck, and Pfizer. Consultant and Advisor for Amgen, Boehringer-Ingelheim, Eli Lilly, Janssen, Merck, Pfizer, Sanofi, and Applied Therapeutics.
Peter Libby, MD (moderator): Consultant and Advisor for Amgen. Advisor for Novo Nordisk.
Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose.Unlabeled and Investigational Usage
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by Pri-Med Institute or DBC Pri-Med, LLC.
Disclaimer
The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, DBC Pri-Med, LLC.
Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients. Data, indications, and guidelines presented in this activity are current as of the activity release date and they are subject to change as new information is published.
CME Questions?
If you have questions about this activity, please email support@pri-med.com or call (877) 477-4633.